Heparanase activity and bone loss in postmenopausal breast cancer patients
- PMID: 16314656
- DOI: 10.1200/JCO.2005.04.0121
Heparanase activity and bone loss in postmenopausal breast cancer patients
Comment on
-
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.J Clin Oncol. 2005 Aug 1;23(22):5126-37. doi: 10.1200/JCO.2005.07.097. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983390 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
